Clinical Trial Update: GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating GM-CSF as maintenance therapy in prostate cancer patients responding to Taxotere (docetaxel).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• GM-CSF (granulocyte-macrophage colony-stimulating factor)
• Taxotere (docetaxel)

Snippet

Sponsor: Oncology Specialists, S.C. | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-05-09